Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy
Micro-Abstract: Activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin and Janus kinase/signal transducer and activator of transcription pathways are described in inflammatory breast cancer (IBC) preclinical data. This retrospective analysis of IBC and invasive ductal carcino...
Gespeichert in:
| Veröffentlicht in: | Clinical breast cancer 2016-04, Vol.16 (2), p.113-122.e1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 122.e1 |
|---|---|
| container_issue | 2 |
| container_start_page | 113 |
| container_title | Clinical breast cancer |
| container_volume | 16 |
| creator | Jhaveri, Komal Teplinsky, Eleonora Silvera, Deborah Valeta-Magara, Amanda Arju, Rezina Giashuddin, Shah Sarfraz, Yasmeen Alexander, Melissa Darvishian, Farbod Levine, Paul H Hashmi, Salman Zolfaghari, Ladan Hoffman, Heather J Singh, Baljit Goldberg, Judith D Hochman, Tsivia Formenti, Silvia Esteva, Francisco J Moran, Meena S Schneider, Robert J |
| description | Micro-Abstract: Activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin and Janus kinase/signal transducer and activator of transcription pathways are described in inflammatory breast cancer (IBC) preclinical data. This retrospective analysis of IBC and invasive ductal carcinoma tumor tissues treated with neoadjuvant chemotherapy showed pathway activity compared with untreated invasive ductal carcinoma, which suggests a potential mechanism of resistance and supports a potential role for targeting these pathways in prospective studies. |
| doi_str_mv | 10.1016/j.clbc.2015.11.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4794410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1526820915002797</els_id><sourcerecordid>1774160077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c576t-6a94a6bd58db5631e718c3ef41944f176c91685d6ab97d52aa05bbef426e3b493</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEoqXwAhyQj1x2a-ePs0Go0rIFulBoRcPZmjiTrhcnXmwnKK_FE-Lslgo4cLKl-b7fePxNFD1ndM4o46fbudSVnMeUZXPG5pTyB9ExK5LFjHLOH4Z7FvPZIqbFUfTEuS2lMU8YfRwdxTzP07TIj6OfF-MOLUivBvBYk7a8-kKgq8mH5cf49KZclgm5Br_5AaN7RT4ZjbLXYMm5VQNat5deG4-dV6BJuQmsHfZeSVKCvUXviGnIums0tC14Y8e9Y90N4AKAnPfSB98bi-A8WUEnJ-iy8WjJZzRQb_sBulDZYGv8nj4-jR41oB0-uztPoq_v3pari9nl1fv1ank5k1nO_YxDkQKv6mxRV1mYG3O2kAk2KSvStGE5lwXji6zmUBV5ncUANKuqUI85JlVaJCfR2YG766sWaxlmtKDFzqoW7CgMKPF3pVMbcWsGkeahA6MB8PIOYM33Hp0XrXIStYYOTe8ECyEwTmmeB2l8kEprnLPY3LdhVExhi62YwhZT2IIxEcIOphd_PvDe8jvdIHh9EGD4pkGhFU4qDH9cK4vSi9qo__PP_rFLrTolQX_DEd3W9LYLAQgmXCyouJnWbdo2loVNy0P_X9Ai09A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1774160077</pqid></control><display><type>article</type><title>Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jhaveri, Komal ; Teplinsky, Eleonora ; Silvera, Deborah ; Valeta-Magara, Amanda ; Arju, Rezina ; Giashuddin, Shah ; Sarfraz, Yasmeen ; Alexander, Melissa ; Darvishian, Farbod ; Levine, Paul H ; Hashmi, Salman ; Zolfaghari, Ladan ; Hoffman, Heather J ; Singh, Baljit ; Goldberg, Judith D ; Hochman, Tsivia ; Formenti, Silvia ; Esteva, Francisco J ; Moran, Meena S ; Schneider, Robert J</creator><creatorcontrib>Jhaveri, Komal ; Teplinsky, Eleonora ; Silvera, Deborah ; Valeta-Magara, Amanda ; Arju, Rezina ; Giashuddin, Shah ; Sarfraz, Yasmeen ; Alexander, Melissa ; Darvishian, Farbod ; Levine, Paul H ; Hashmi, Salman ; Zolfaghari, Ladan ; Hoffman, Heather J ; Singh, Baljit ; Goldberg, Judith D ; Hochman, Tsivia ; Formenti, Silvia ; Esteva, Francisco J ; Moran, Meena S ; Schneider, Robert J</creatorcontrib><description>Micro-Abstract: Activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin and Janus kinase/signal transducer and activator of transcription pathways are described in inflammatory breast cancer (IBC) preclinical data. This retrospective analysis of IBC and invasive ductal carcinoma tumor tissues treated with neoadjuvant chemotherapy showed pathway activity compared with untreated invasive ductal carcinoma, which suggests a potential mechanism of resistance and supports a potential role for targeting these pathways in prospective studies.</description><identifier>ISSN: 1526-8209</identifier><identifier>EISSN: 1938-0666</identifier><identifier>DOI: 10.1016/j.clbc.2015.11.006</identifier><identifier>PMID: 26774497</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Biomarkers ; Biomarkers, Tumor - metabolism ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Carcinoma, Ductal, Breast - drug therapy ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Female ; Follow-Up Studies ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunoenzyme Techniques ; Inflammatory breast cancer ; Inflammatory Breast Neoplasms - drug therapy ; Inflammatory Breast Neoplasms - metabolism ; Inflammatory Breast Neoplasms - pathology ; Janus Kinase 2 - metabolism ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - metabolism ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics and Gynecology ; Prognosis ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Resistance to chemotherapy ; Signal Transduction - drug effects ; Signaling pathways ; STAT3 Transcription Factor - metabolism ; Survival Rate ; Targeted therapies ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>Clinical breast cancer, 2016-04, Vol.16 (2), p.113-122.e1</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c576t-6a94a6bd58db5631e718c3ef41944f176c91685d6ab97d52aa05bbef426e3b493</citedby><cites>FETCH-LOGICAL-c576t-6a94a6bd58db5631e718c3ef41944f176c91685d6ab97d52aa05bbef426e3b493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1526820915002797$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26774497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jhaveri, Komal</creatorcontrib><creatorcontrib>Teplinsky, Eleonora</creatorcontrib><creatorcontrib>Silvera, Deborah</creatorcontrib><creatorcontrib>Valeta-Magara, Amanda</creatorcontrib><creatorcontrib>Arju, Rezina</creatorcontrib><creatorcontrib>Giashuddin, Shah</creatorcontrib><creatorcontrib>Sarfraz, Yasmeen</creatorcontrib><creatorcontrib>Alexander, Melissa</creatorcontrib><creatorcontrib>Darvishian, Farbod</creatorcontrib><creatorcontrib>Levine, Paul H</creatorcontrib><creatorcontrib>Hashmi, Salman</creatorcontrib><creatorcontrib>Zolfaghari, Ladan</creatorcontrib><creatorcontrib>Hoffman, Heather J</creatorcontrib><creatorcontrib>Singh, Baljit</creatorcontrib><creatorcontrib>Goldberg, Judith D</creatorcontrib><creatorcontrib>Hochman, Tsivia</creatorcontrib><creatorcontrib>Formenti, Silvia</creatorcontrib><creatorcontrib>Esteva, Francisco J</creatorcontrib><creatorcontrib>Moran, Meena S</creatorcontrib><creatorcontrib>Schneider, Robert J</creatorcontrib><title>Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy</title><title>Clinical breast cancer</title><addtitle>Clin Breast Cancer</addtitle><description>Micro-Abstract: Activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin and Janus kinase/signal transducer and activator of transcription pathways are described in inflammatory breast cancer (IBC) preclinical data. This retrospective analysis of IBC and invasive ductal carcinoma tumor tissues treated with neoadjuvant chemotherapy showed pathway activity compared with untreated invasive ductal carcinoma, which suggests a potential mechanism of resistance and supports a potential role for targeting these pathways in prospective studies.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Carcinoma, Ductal, Breast - drug therapy</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Inflammatory breast cancer</subject><subject>Inflammatory Breast Neoplasms - drug therapy</subject><subject>Inflammatory Breast Neoplasms - metabolism</subject><subject>Inflammatory Breast Neoplasms - pathology</subject><subject>Janus Kinase 2 - metabolism</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - metabolism</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Resistance to chemotherapy</subject><subject>Signal Transduction - drug effects</subject><subject>Signaling pathways</subject><subject>STAT3 Transcription Factor - metabolism</subject><subject>Survival Rate</subject><subject>Targeted therapies</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>1526-8209</issn><issn>1938-0666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks9u1DAQxiMEoqXwAhyQj1x2a-ePs0Go0rIFulBoRcPZmjiTrhcnXmwnKK_FE-Lslgo4cLKl-b7fePxNFD1ndM4o46fbudSVnMeUZXPG5pTyB9ExK5LFjHLOH4Z7FvPZIqbFUfTEuS2lMU8YfRwdxTzP07TIj6OfF-MOLUivBvBYk7a8-kKgq8mH5cf49KZclgm5Br_5AaN7RT4ZjbLXYMm5VQNat5deG4-dV6BJuQmsHfZeSVKCvUXviGnIums0tC14Y8e9Y90N4AKAnPfSB98bi-A8WUEnJ-iy8WjJZzRQb_sBulDZYGv8nj4-jR41oB0-uztPoq_v3pari9nl1fv1ank5k1nO_YxDkQKv6mxRV1mYG3O2kAk2KSvStGE5lwXji6zmUBV5ncUANKuqUI85JlVaJCfR2YG766sWaxlmtKDFzqoW7CgMKPF3pVMbcWsGkeahA6MB8PIOYM33Hp0XrXIStYYOTe8ECyEwTmmeB2l8kEprnLPY3LdhVExhi62YwhZT2IIxEcIOphd_PvDe8jvdIHh9EGD4pkGhFU4qDH9cK4vSi9qo__PP_rFLrTolQX_DEd3W9LYLAQgmXCyouJnWbdo2loVNy0P_X9Ai09A</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Jhaveri, Komal</creator><creator>Teplinsky, Eleonora</creator><creator>Silvera, Deborah</creator><creator>Valeta-Magara, Amanda</creator><creator>Arju, Rezina</creator><creator>Giashuddin, Shah</creator><creator>Sarfraz, Yasmeen</creator><creator>Alexander, Melissa</creator><creator>Darvishian, Farbod</creator><creator>Levine, Paul H</creator><creator>Hashmi, Salman</creator><creator>Zolfaghari, Ladan</creator><creator>Hoffman, Heather J</creator><creator>Singh, Baljit</creator><creator>Goldberg, Judith D</creator><creator>Hochman, Tsivia</creator><creator>Formenti, Silvia</creator><creator>Esteva, Francisco J</creator><creator>Moran, Meena S</creator><creator>Schneider, Robert J</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160401</creationdate><title>Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy</title><author>Jhaveri, Komal ; Teplinsky, Eleonora ; Silvera, Deborah ; Valeta-Magara, Amanda ; Arju, Rezina ; Giashuddin, Shah ; Sarfraz, Yasmeen ; Alexander, Melissa ; Darvishian, Farbod ; Levine, Paul H ; Hashmi, Salman ; Zolfaghari, Ladan ; Hoffman, Heather J ; Singh, Baljit ; Goldberg, Judith D ; Hochman, Tsivia ; Formenti, Silvia ; Esteva, Francisco J ; Moran, Meena S ; Schneider, Robert J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c576t-6a94a6bd58db5631e718c3ef41944f176c91685d6ab97d52aa05bbef426e3b493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Carcinoma, Ductal, Breast - drug therapy</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Inflammatory breast cancer</topic><topic>Inflammatory Breast Neoplasms - drug therapy</topic><topic>Inflammatory Breast Neoplasms - metabolism</topic><topic>Inflammatory Breast Neoplasms - pathology</topic><topic>Janus Kinase 2 - metabolism</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - metabolism</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Resistance to chemotherapy</topic><topic>Signal Transduction - drug effects</topic><topic>Signaling pathways</topic><topic>STAT3 Transcription Factor - metabolism</topic><topic>Survival Rate</topic><topic>Targeted therapies</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jhaveri, Komal</creatorcontrib><creatorcontrib>Teplinsky, Eleonora</creatorcontrib><creatorcontrib>Silvera, Deborah</creatorcontrib><creatorcontrib>Valeta-Magara, Amanda</creatorcontrib><creatorcontrib>Arju, Rezina</creatorcontrib><creatorcontrib>Giashuddin, Shah</creatorcontrib><creatorcontrib>Sarfraz, Yasmeen</creatorcontrib><creatorcontrib>Alexander, Melissa</creatorcontrib><creatorcontrib>Darvishian, Farbod</creatorcontrib><creatorcontrib>Levine, Paul H</creatorcontrib><creatorcontrib>Hashmi, Salman</creatorcontrib><creatorcontrib>Zolfaghari, Ladan</creatorcontrib><creatorcontrib>Hoffman, Heather J</creatorcontrib><creatorcontrib>Singh, Baljit</creatorcontrib><creatorcontrib>Goldberg, Judith D</creatorcontrib><creatorcontrib>Hochman, Tsivia</creatorcontrib><creatorcontrib>Formenti, Silvia</creatorcontrib><creatorcontrib>Esteva, Francisco J</creatorcontrib><creatorcontrib>Moran, Meena S</creatorcontrib><creatorcontrib>Schneider, Robert J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical breast cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jhaveri, Komal</au><au>Teplinsky, Eleonora</au><au>Silvera, Deborah</au><au>Valeta-Magara, Amanda</au><au>Arju, Rezina</au><au>Giashuddin, Shah</au><au>Sarfraz, Yasmeen</au><au>Alexander, Melissa</au><au>Darvishian, Farbod</au><au>Levine, Paul H</au><au>Hashmi, Salman</au><au>Zolfaghari, Ladan</au><au>Hoffman, Heather J</au><au>Singh, Baljit</au><au>Goldberg, Judith D</au><au>Hochman, Tsivia</au><au>Formenti, Silvia</au><au>Esteva, Francisco J</au><au>Moran, Meena S</au><au>Schneider, Robert J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy</atitle><jtitle>Clinical breast cancer</jtitle><addtitle>Clin Breast Cancer</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>16</volume><issue>2</issue><spage>113</spage><epage>122.e1</epage><pages>113-122.e1</pages><issn>1526-8209</issn><eissn>1938-0666</eissn><abstract>Micro-Abstract: Activation of the phosphatidylinositide-3-kinase/mammalian target of rapamycin and Janus kinase/signal transducer and activator of transcription pathways are described in inflammatory breast cancer (IBC) preclinical data. This retrospective analysis of IBC and invasive ductal carcinoma tumor tissues treated with neoadjuvant chemotherapy showed pathway activity compared with untreated invasive ductal carcinoma, which suggests a potential mechanism of resistance and supports a potential role for targeting these pathways in prospective studies.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26774497</pmid><doi>10.1016/j.clbc.2015.11.006</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1526-8209 |
| ispartof | Clinical breast cancer, 2016-04, Vol.16 (2), p.113-122.e1 |
| issn | 1526-8209 1938-0666 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4794410 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - pharmacology Biomarkers Biomarkers, Tumor - metabolism Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Carcinoma, Ductal, Breast - drug therapy Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Female Follow-Up Studies Hematology, Oncology and Palliative Medicine Humans Immunoenzyme Techniques Inflammatory breast cancer Inflammatory Breast Neoplasms - drug therapy Inflammatory Breast Neoplasms - metabolism Inflammatory Breast Neoplasms - pathology Janus Kinase 2 - metabolism Middle Aged Neoadjuvant Therapy Neoplasm Invasiveness Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - pathology Neoplasm Staging Obstetrics and Gynecology Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Resistance to chemotherapy Signal Transduction - drug effects Signaling pathways STAT3 Transcription Factor - metabolism Survival Rate Targeted therapies TOR Serine-Threonine Kinases - metabolism |
| title | Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T00%3A25%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperactivated%20mTOR%20and%20JAK2/STAT3%20Pathways:%20Molecular%20Drivers%20and%20Potential%20Therapeutic%20Targets%20of%20Inflammatory%20and%20Invasive%20Ductal%20Breast%20Cancers%20After%20Neoadjuvant%20Chemotherapy&rft.jtitle=Clinical%20breast%20cancer&rft.au=Jhaveri,%20Komal&rft.date=2016-04-01&rft.volume=16&rft.issue=2&rft.spage=113&rft.epage=122.e1&rft.pages=113-122.e1&rft.issn=1526-8209&rft.eissn=1938-0666&rft_id=info:doi/10.1016/j.clbc.2015.11.006&rft_dat=%3Cproquest_pubme%3E1774160077%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1774160077&rft_id=info:pmid/26774497&rft_els_id=S1526820915002797&rfr_iscdi=true |